Micell Forms Alliance for the Development of Drug-Eluting Stents, Balloons
January 13, 2009 - Micell Technologies, a development-stage biomedical device company dedicated to developing innovative interventional cardiology systems, has obtained the rights to Maxcor's CE-marked Genius MAGIC Cobalt Chromium Coronary Stent System for the purpose of developing and marketing drug-eluting stents (DES) based on Micell's prop coating technology.
The companies also entered into an agreement to develop drug-eluting balloon (DEB) products for cardiovascular applications.
Micell has developed a drug-polymer formulation that is said to precisely and consistently control drug elution and the duration of polymer exposure. The coating has the potential to deliver a precise therapeutic solution for coronary artery disease without the long-term safety concerns of currently available DES. The in-licensing of the Genius MAGIC Cobalt Chromium Coronary Stent System provides what the company believes is the optimal bare-metal stent product for the further development of the company's drug-polymer coating. The company believes that DEB will advance the treatment of many clinical conditions while minimizing risks or side-effects of these treatments.
For more information: www.micell.com
More like this
- Micell Forms Alliance for the Development of Drug-Eluting Stents, Balloons
- Drug-Eluting Stents and Balloons Result in Good Outcomes When Treating Patients With Bare Metal Stent Restenosis
- Medtronic Begins European Launch of Drug-Eluting Stent
- Use Of Drug-Eluting Balloons With Bare Metal Stents Show No Superiority Over Drug-Eluting Stents
- Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent